National Institute for Public Health and the Environment, Centre for Prevention and Health Services Research, Bilthoven, The Netherlands.
Eur J Public Health. 2011 Apr;21(2):260-4. doi: 10.1093/eurpub/ckq069. Epub 2010 Jun 9.
In recent years the literature regarding the cost-effectiveness of disease prevention and health promotion has grown exponentially. Aim of this study is to investigate: (i) how many and what type of economic evaluations have been published in 2008, (ii) the diseases or health problems World Health Organization International Classification of Diseases 10 chapters the economic evaluations of preventive interventions focus on, in relation to the global burden of disease and (iii) the cost-effectiveness of these interventions.
Literature study of economic evaluations on preventive interventions in PubMed and Scopus.
In 2008, 232 economic evaluations of preventive interventions have been published. Of these studies, 75% (n = 175) used costs per (Quality Adjusted) Life Year [(QA)LY] gained as outcome measure. Most economic evaluations focus on the prevention of infectious diseases (31.5%, n = 73) and cancers (21%, n = 49) Infectious diseases are responsible for the highest global burden of disease (19.8%), followed by mental and behavioural disorders (11.7%). Of the included economic evaluations, 80% remained below a threshold of €50 000 and 60% below €20 000 per (QA)LY.
This study shows that many economic evaluations of preventive interventions use a generic outcome measure. This adds to the comparability of different studies on the cost-effectiveness of prevention. Although the focus of published economic evaluations in general corresponds well with those diseases that cause a large share of the world's burden of disease, mental and behavioural diseases and diseases of the respiratory system remain underrepresented. Finally, it appears that the vast majority of published economic evaluations of preventive measures show favourable cost-effectiveness levels.
近年来,关于疾病预防和健康促进的成本效益的文献呈指数级增长。本研究旨在调查:(i)2008 年发表了多少篇和哪些类型的经济评估;(ii)世界卫生组织国际疾病分类第 10 章中预防性干预措施的经济评估针对哪些疾病或健康问题,与全球疾病负担有关;(iii)这些干预措施的成本效益。
在 PubMed 和 Scopus 中对预防干预措施的经济评估进行文献研究。
2008 年发表了 232 篇预防干预措施的经济评估。在这些研究中,75%(n=175)使用每获得(质量调整)生命年的成本[(质量调整)生命年]作为结果测量。大多数经济评估侧重于预防传染病(31.5%,n=73)和癌症(21%,n=49)。传染病占全球疾病负担的比例最高(19.8%),其次是精神和行为障碍(11.7%)。在纳入的经济评估中,80%低于 50000 欧元,60%低于 20000 欧元/(质量调整)生命年。
本研究表明,许多预防干预措施的经济评估使用通用的结果衡量标准。这增加了不同预防成本效益研究的可比性。尽管发表的经济评估的重点通常与那些导致全球疾病负担很大一部分的疾病相对应,但精神和行为疾病以及呼吸系统疾病的代表性仍然不足。最后,似乎绝大多数发表的预防措施的经济评估都显示出有利的成本效益水平。